New hope for brain cancer patients: experimental pastille combo targets recurrent glioma

NCT ID NCT06011109

Recruiting now Disease control Sponsor: Aveta Biomics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study tests whether adding an experimental pastille (APG-157) to standard bevacizumab can help people with recurrent high-grade glioma, a serious brain cancer. About 30 participants will take APG-157 daily by dissolving pastilles in their mouth, while continuing bevacizumab. Researchers will track survival, tumor changes on scans, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA MULTIFORME GLIOBLASTOMA MULTIFORME GLIOMA